Universidad Peruana Cayetano Heredia

Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping

Mostrar el registro sencillo del ítem

dc.contributor.author Beck, Hans-Peter
dc.contributor.author Wampfler, Rahel
dc.contributor.author Carter, Nick
dc.contributor.author Koh, Gavin
dc.contributor.author Osorio, Lyda
dc.contributor.author Rueangweerayut, Ronnatrai
dc.contributor.author Krudsood, Srivcha
dc.contributor.author Lacerda, Marcus V.
dc.contributor.author Llanos Cuentas, Elmer Alejandro
dc.contributor.author Duparc, Stephan
dc.contributor.author Rubio, Justin P.
dc.contributor.author Green, Justin A.
dc.date.accessioned 2019-02-06T14:57:40Z
dc.date.available 2019-02-06T14:57:40Z
dc.date.issued 2015
dc.identifier.uri https://hdl.handle.net/20.500.12866/5487
dc.description.abstract UNLABELLED: Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose-response pattern was evident for heterologous recurrences of P. vivax infection. Rates of homologous recurrence of P. vivax infection appear to be clinically useful for comparing drug efficacy for the prevention of P. vivax infection relapse. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Journal of Infectious Diseases
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Genotype en_US
dc.subject Plasmodium vivax en_US
dc.subject Double-Blind Method en_US
dc.subject efficacy en_US
dc.subject Dose-Response Relationship, Drug en_US
dc.subject Plasmodium vivax/genetics en_US
dc.subject Secondary Prevention en_US
dc.subject Aminoquinolines/administration & dosage/therapeutic use en_US
dc.subject antihypnozoite en_US
dc.subject Antimalarials/administration & dosage/therapeutic use en_US
dc.subject Chloroquine/administration & dosage/therapeutic use en_US
dc.subject genotyping en_US
dc.subject Malaria, Vivax/drug therapy en_US
dc.subject Primaquine/administration & dosage/therapeutic use en_US
dc.subject tafenoquine en_US
dc.title Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1093/infdis/jiv508
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn 1537-6613


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas